SequelSEC

Bicara Therapeutics Inc. BCAX

Pharmaceutical Preparations · CIK 0002023658 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$155.60M
Fiscal year ended 2025-12-31
Free cash flow
-$107.11M
Fiscal year ended 2025-12-31

Bicara Therapeutics Inc. (BCAX) reported net income of -$137.95M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Bicara Therapeutics Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Bicara Therapeutics Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$155.60M-$82.39M-$39.89M
Net income-$137.95M-$68.00M-$51.98M
Research & developmentUnavailable$63.60M$30.60M
Weighted-average diluted sharesUnavailableshares 16.81Bshares 580.11M
Pretax income-$137.73M-$67.81M-$51.98M
Income tax expense$217.00K$187.00K$5.00K
Diluted EPS$-2.52$-4.05$-89.61
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$30.51M$18.77M$9.27M
Selling & marketingUnavailableUnavailableUnavailable

Balance

Bicara Therapeutics Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$96.68M$489.71M$230.44M
Total assets$430.99M$510.00M$233.98M
Current assets$422.05M$502.53M$231.07M
Total liabilities$29.54M$18.12M$15.47M
Current liabilities$28.95M$17.99M$15.08M
Total equity incl. NCI$401.45M$491.88M-$148.77M
Temporary (mezzanine) equityUnavailable$0$367.28M
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailable

Cash flow

Bicara Therapeutics Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$106.83M-$74.75M-$45.63M
Capital expenditures$280.00K$71.00K$586.00K
Investing cash flow-$318.45M-$9.00K-$586.00K
Financing cash flow$32.26M$334.03M$272.50M
Net change in cash-$393.03M$259.27M$226.28M
Stock-based compensation$15.01M$7.40M$1.90M
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

Bicara Therapeutics Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flow-$107.11M-$74.82M-$46.21M
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio14.58x27.93x15.32x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BCAX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-11View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-03-30View SEC filing
10-Q · Filed 2025-11-10View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.